Gufic BioSciences Share Price

Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients. Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network. The Company is ranked among the top 100 pharmaceutical companies in India.Gufic is a leading manufacturer of lyophilized injections in India, with a stateoftheart automated lyophilization plant located in Navsari, Gujarat. The Company was incorporated in July, 1984. The recent addition of the Indore manufacturing facility has further solidified Gufics position as one of the worlds largest producers of lyophilized injections. These products cover therapeutic areas, including antibiotics, antifungals, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs).The Company made a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 4042 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Choksi and Gandhi family, the promoters of GBL, have a longstanding presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets. Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil.In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held.Gufic has divested brands in the ethical pharma business in a sellers market. The company plan to invest further in RD activities and aggressively enter the herbal product and consumer product segments, where it foresee a huge potential. While benefiting from the rich, traditional knowledge base in India, it would like to operate from an area of strength in the herbal products segment.In 202021, Gufic Lifesciences Private Limited amalgamated with the Company through the Scheme of Amalgamation which became effective from May 21, 2021. GUFIC UK LIMITED (GUL), a wholly owned subsidiary of the Company, was incorporated in United Kingdom on March 15, 2022. Similarly, in 2023, Gufic Ireland Limited (GIL) was incorporated on March 02, 2023.

For the full year FY2026–2027, revenue reached ₹946.66 crore and profit touched at ₹64.21 crore. As of Jun '26, Gufic BioSciences’s market capitalisation stood at ₹3,782.15 crores. Shareholding as of Jun '26 shows promoters holding 72.5%, with FIIs at 0.5%, DIIs at 3.6%, and public at 23.4%.